Involvement of bone morphogenetic protein-4 in GH regulation by octreotide and bromocriptine in rat pituitary GH3 cells

Journal of Endocrinology

Volumn 197, Issue 1, 2008, Pages 159-169

  Miyoshi, Tomoko ^a   Otsuka, Fumio ^a   Otani, Hiroyuki ^a   Inagaki, Kenichi ^a   Goto, Junko ^a   Yamashita, Misuzu ^a   Ogura, Toshio ^a   Iwasaki, Yasumasa ^b   Makino, Hirofumi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b KOCHI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN 4; BONE MORPHOGENETIC PROTEIN 6; BONE MORPHOGENETIC PROTEIN RECEPTOR 1; BONE MORPHOGENETIC PROTEIN RECEPTOR 1A; BONE MORPHOGENETIC PROTEIN RECEPTOR 1B; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; BROMOCRIPTINE; CYCLIC AMP; DOPAMINE RECEPTOR STIMULATING AGENT; FORSKOLIN; GROWTH HORMONE; INHIBITOR OF DIFFERENTIATION 1; OCTREOTIDE; PROLACTIN; SMAD PROTEIN; SMAD1 PROTEIN; SMAD5 PROTEIN; SMAD8 PROTEIN; SOMATOSTATIN DERIVATIVE;

ANIMAL CELL; ARTICLE; CELL STRAIN GH3; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; GENETIC TRANSCRIPTION; HORMONAL REGULATION; HORMONE SYNTHESIS; HYPOPHYSIS ADENOMA; INHIBITION KINETICS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

ANIMALS; BONE MORPHOGENETIC PROTEIN 4; BONE MORPHOGENETIC PROTEIN 6; BONE MORPHOGENETIC PROTEIN RECEPTORS; BROMOCRIPTINE; CELL LINE, TUMOR; CYCLIC AMP; DOSE-RESPONSE RELATIONSHIP, DRUG; FORSKOLIN; GROWTH HORMONE; OCTREOTIDE; RATS; RECEPTORS, SOMATOSTATIN;

EID: 42449136234     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1677/JOE-07-0549     Document Type: Article

References (44)

1. Aoki H, Fujii M, Imamura T, Yagi K, Takehara K, Kato M & Miyazono K 2001 Synergistic effects of different bone morphogenetic protein type I receptors on alkaline phosphatase induction. Journal of Cell Science 114 1483-1489.
2. Balsa JA, Varela C, Lucas T, Garcia-Uria J, Barcelo B & Sancho-Rof JM 2002 Varying additive effects of bromocriptine with two somatostarin analogs in cultures of GH-secreting adenomas. Hormone and Metabolic Research 34 435-440.
3. Chen ZP, Xu S, Lightman SL, Hall L & Levy A 1997 Intracellular calcium ion responses to somatostatin in cells from human somatotroph adenomas. Clinical Endocrinology 46 45-53.
4. Chiodini PG, Cozzi R, Dallabonzana D, Oppizzi G, Verde G, Petroncini M, Liuzzi A & del Pozo E 1987 Medical treatment of acromegaly with SMS 201-995, a somatostatin analog: a comparison with bromocriptine. Journal of Clinical Endocrinology and Metabolism 64 447-453.
5. Cozzi R, Attanasio R, Lodrini S & Lasio G 2004 Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status. Clinical Endocrinology 61 209-215.
6. Dasen JS & Rosenfeld MG 2001 Signaling and transcriptional mechanisms in pituitary development. Annual Review of Neuroscicnce 24 327-355. ten Dijke P, Yamashita H, Sampath TK, Reddi AH, Estevez M, Riddle DL, Ichijo H, Heldin C-H & Miyazono K 1994 Identification of type I receptors for osreogenic protein-1 and bone morphogenetic protein-4. Journal of Biological Chemistry 269 16985-16988.
7. Duhau L, Grassi J, Grouselle D, Enjalbert A & Grognet JM 1991 An enzyme immunoassay for rat prolactin: application to the determination of plasma levels. Journal of Immmunoassay 12 233-250.
8. Ebisawa T, Tada K, Kitajima I, Tojo K, Sampath TK, Kawabati M, Miyazono K & Imamura T 1999 Characterization of bone morphogenetic protein-6 signaling pathways in osteoblast differentiation. Journal of Cell Science 112 3519-3527.
9. Ezan E, Laplante E, Bluet-Pajot MT. Mounier L Mamas S, Grouselle D, Grognet JM & Kordon C 1997 An enzyme immunoassay for rat growth hormone: validation and application to the determination of plasma levels and in vitro release. Journal of Immunoassay 18 335-356.
10. Flogstad AK, Halse J, Grass P, Abisch E, Djoseland O, Kutz K, Bodd E & Jervell J 1994 A comparison of octreotide, bromocriptine, or a combination of both drugs in acromegaly. Journal of Clinical Endocrinology and Metabolism 79 461-465.
11. Fredstorp L, Kutz K & Werner S 1994 Treatment with octreotide and bromocriptine in patients with acromegaly: an open pharmacodynamic interaction study. Clinical Endocrinology 41 103-108.
12. Giacomini D, Paez-Pereda M, Theodoropoulou M, Labeur M, Refojo D, Gerez J, Chervin A, Berner S, Losa M, Buchfelder M et al. 2006 Bone morphogenetic protein-4 inhibits corticotroph tumor cells: involvement in the retinoic acid inhibitory action. Endocrinology 147 247-256.
13. Inagaki K, Otsuka E Suzuki J, Kano Y, Takeda M, Miyoshi T, Otani H, Mimuma Y, Ogura T & Makino, H 2006 Involvement of bone morphogenetic protein-6 in differential regulation of aldosterone production by angiotensin II and potassium in human adrenocortical cells. Endocrinology 147 2681-2689.
14. Jaffe CA & Barkan AL 1992 Treatment of acromegaly with dopamine agonists. Endocrinology and Metabolism Clinics of North America 21 713-735.
15. Johnston JM, Wood DF, Bolaji EA & Johnston DG 1991 The dopamine D2 receptor is expressed in GH3 cells. Journal of Molecular Endocrinology 7 131-136.
16. Kano Y, Otsuka F, Takeda M, Suzuki J, Inagaki K, Miyoshi T, Miyamoto M, Otani H, Ogura T & Makino H 2005 Regulatory roles of bone morphogenetic proteins and glucocorticoids in catecholamine production by rat pheochromocytoma cells. Endocrinology 146 5332-5340.
17. Kioussi C, Carriere C & Rosenfeld MG 1999 A model for the development of the hypothalamic-pituirary axis: transcribing the hypophysis. Mechanisms of Development 81 23-35.
18. Lamberts SW, Zweens M, Verschoor L & del Pozo E 1986 A comparison among the growth hormone-lowering effects in acromegaly of the somatostatin analog SMS 201-995, bromocriptine, and the combination of both drugs. Journal of Clinical Endocrinology and Metabolism 63 16-19.
19. Lamberts SW, Verleun T, Hofland L & Del Pozo E 1987 A comparison between the effects of SMS 201-995, bromocriptine and a combination of both drugs on hormone release by the cultured pituitary tumour cells of acromegalic patients. Clinical Endocrinology 27 11-23.
20. Li JK, Chow CC, Yeung VT, Mak TW, Ko GT, Swaminathan R, Chan JC & Cockram CS 2000 Treatment of Chinese acromegaly with a combination of bromocriptine and octreotide. Australian a New Zealand Journal of Medicine 30 457-461.
21. Liu F, Ventura F, Doody J & Massague J 1995 Human type II receptor for bone morphogenic proteins (BMPs): extension ofthe two-kinase receptor model to the BMPs. Molecular and Cellular Biology 15 3479-3486.
22. Marzullo P, Ferone D, Di Somina C, Pivonello R, Filippella M, Lombardi G & Colao A 1999 Efficacy of combined treatment with lanreotide and cabergoline in selected therapy-resistant acromegalic patients. Pituitary 1 115-120.
23. Miyoshi T, Otsuka F, Inagaki K, Otani H, Takeda M, Suzuki J, Goto J, Ogura T & Makino H 2007 Differential regulation of steroidogenesis by bone morphogenetic proteins in granulosa cells: involvement of extracellularly regulated kinase signaling and oocyte actions in follicle-stimulating hormone-induced estrogen production. Endocrinology 148 337-345.
24. Moore RK, Otsuka F & Shimasaki S 2003 Molecular basis of bone morphogenetic protein-15 signaling in granulosa cells. Journal of Biological Chemistry 278 304-310.
25. Nohno T, Ishikawa T, Saito T, Hosokawa K, Noji S, Wolsing DH & Rosenbaum JS 1995 Identification of a human type II receptor for bone morphogenetic protein-4 that forms differential heteromeric complexes with bone morphogenetic protein type I receptors. Journal of Biological Chemistry 270 22522-22526.
26. Otani H, Otsuka F, Inagaki K, Takeda M, Miyoshi T, Suzuki J, Mukai T, Ogura T & Makino H 2007 Antagonistic effects of bone morphogenetic protein-4 and -7 on renal mesangial cell proliferation induced by aldosterone through MAPK activation. American Journal of Physiology. Renal Physiology 292 F1513-F1525.
27. Otsuka F & Shimasaki S 2002 A novel function of bone morphogenetic protein-15 in the pituitary: selective synthesis and secretion of FSH by gonadotropes. Endocrinology 143 4938-4941.
28. Otsuka F, Yao Z, Lee TH, Yamamoto S, Erickson GF & Shimasaki S 2000 Bone morphogenetic protein-15: identification of target cells and biological functions. Journal of Biological Chemistry 275 39523-39528.
29. Otsuka F, Moore RK & Shimasaki S 2001 Biological function and cellular mechanism of bone morphogenetic protein-6 in the ovary. Journal of Biological Chemistry 276 32889-32895.
30. Paez-Pereda M, Giacomini D, Refojo D, Nagashima AC, Hopfner U, Grubler Y, Chervin A, Goldberg V, Goya R, Hentges ST et al. 2003 Involvement of bone morphogenetic protein 4 (BMP-4) in pituitary prolactinoma pathogenesis through a Smad/estrogen receptor crosstalk. PNAS 100 1034-1039.
31. Reisine T & Bell GI 1995 Molecular biology of somatostatin receptors. Endocrine Reviews 16 427-442.
32. Rocheville M, Lange DC, Kumar U, Patel SC, Patel RC & Patel YC 2000 Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science 288 154-157.
33. Rosenzweig BL, Imamura T, Okadome T, Cox GN, Yamashita H, ten Dijke P, Heldin C-H & Miyazono K 1995 Cloning and characterization of a human type II receptor for bone morphogenetic proteins. PNAS 92 7632-7636.
34. Scully KM & Rosenfeld MG 2002 Pituitary development: regulatory codes in mammalian organogenesis. Science 295 2231-2235.
35. Shimon I, Yan X, Taylor JE, Weiss MH, Culler MD & Melmed S 1997 Somatoscatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors. Journal of Clinical Investigation 100 2386-2392.
36. Spada A, Arosio M, Bochicchio D, Bazzoni N, Vallar L, Bassetti M & Faglia G 1990 Clinical, biochemical, and morphological correlates in patients bearing growth homione-secreting pituitary rumors with or without constitutively active adenylyl cyclase. Journal of Clinical Endocrinology and Metabolism 71 1421-1426.
37. Suzuki J, Otsuka F, Inagaki K, Takeda M, Ogura T & Makino H 2004 Novel action of activin and bone morphogenetic protein in regulating aldosterone production by human adrenocortical cells. Endocrinology 145 639-649.
38. Suzuki J, Otsuka F, Takeda M, Inagaki K, Miyoshi T, Mimura Y, Ogura T, Doihara H & Makino H 2005 Functional roles of the bone morphogenetic protein system in thyrotropin signaling in porcine thyroid cells. Biochemical and Biophysical Research Communications 327 1124-1130.
39. Takano K, Yasufuku-Takano J, Teramoto A & Fujita T 1997 Gi3 mediates somatostatin-induced activation of an inwardly rectifying K+ current in human growth hormone-secreting adenoma cells. Endocrinology 138 2405-2409.
40. Takeda M, Otsuka F, Suzuki J, Kishida M, Ogura T, Tamiya T & Makino H 2003 Involvement of activin/BMP system in development of human pituitary gonadotropinomas and nonfunctioning adenomas. Biochemical and Biophysical Research Communications 306 812-818.
41. Takeda M, Otsuka F, Otani H, Inagaki K, Miyoshi T, Suzuki J, Mimura Y, Ogura T & Makino H 2007 Effects of peroxisome proliferator-activated receptor activation on gonadotropin transcription and cell mitosis induced by bone morphogenetic proteins in mouse gonadotrope LβT2 cells. Journal of Endocrinology 194 87-99.
42. Wagenaar AH, Harris AG, van der Lely AJ & Lamberts SW 1991 Dynamics of the acute effects of octreotide, bromocriptine and both drugs in combination oil growth hormone secretion in acromegaly. Acta Endocrinologica 125 637-642.
43. Yamashita H, ten Dijke P, Huylebroeck D, Sampath TK, Andries M, Smith JC, Heldin C-H & Miyazono K 1995 Osteogenic protein-1 binds to activin type II receptors and induces certain activin-like effects. Journal of Cell Biology 130 217-226.
44. Yang SK, Parkington HC, Blake AD, Keating DJ & Chen C 2005 Somatostatin increases voltage-gated K+ currents in GH3 cells through activation of multiple somatostatin receptors. Endocrinology 146 4975-4984.